577
Views
37
CrossRef citations to date
0
Altmetric
Research Article

Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis

, , , , &
Pages 2423-2429 | Received 08 Mar 2012, Accepted 14 May 2012, Published online: 18 Jun 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

M. L. Donker & G. J. Ossenkoppele. (2020) Evaluating ivosidenib for the treatment of acute myeloid leukemia. Expert Opinion on Pharmacotherapy 21:18, pages 2205-2213.
Read now
Juan Eduardo Megías-Vericat, Octavio Ballesta-López, Eva Barragán & Pau Montesinos. (2019) IDH1-mutated relapsed or refractory AML: current challenges and future prospects. Blood and Lymphatic Cancer: Targets and Therapy 9, pages 19-32.
Read now
Hsin-An Hou & Hwei-Fang Tien. (2016) Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility. Expert Review of Hematology 9:5, pages 447-469.
Read now
Wen-Jian Liu, Xiao-Hong Tan, Xiu-Ping Luo, Bao-Ping Guo, Zhou-Ji Wei, Qing Ke, Sha He & Hong Cen. (2014) Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis. Leukemia & Lymphoma 55:12, pages 2691-2698.
Read now

Articles from other publishers (33)

Yoshito Gando & Takeo Yasu. (2023) A Simple HPLC-UV Method for Ivosidenib Determination in Human Plasma. Journal of Chromatographic Science.
Crossref
Yao Qin, Kai Shen, Ting Liu & Hongbing Ma. (2023) Prognostic value of IDH2R140 and IDH2R172 mutations in patients with acute myeloid leukemia: a systematic review and meta-analysis. BMC Cancer 23:1.
Crossref
Hae J. Park & Mark A. Gregory. (2023) Acute myeloid leukemia in elderly patients: New targets, new therapies. Aging and Cancer 4:2, pages 51-73.
Crossref
Rakesh Sahu, Rakhi Mishra, Rajnish Kumar, Salahuddin, Chandana Majee, Avijit Mazumder & Ajay Kumar. (2022) Pyridine Moiety: An Insight into Recent Advances in the Treatment of Cancer. Mini-Reviews in Medicinal Chemistry 22:2, pages 248-272.
Crossref
Sung ChoeHongfang Wang, Courtney D. DiNardo, Eytan M. SteinStéphane de Botton, Gail J. Roboz, Jessica K. AltmanAlice S. MimsJustin M. WattsDaniel A. Pollyea, Amir T. Fathi, Martin S. TallmanHagop M. Kantarjian, Richard M. Stone, Lynn Quek, Zenon KonteatisLenny DangBrandon NicolayParham NejadGuowen LiuVickie ZhangHua LiuMeredith GoldwasserWei LiuKevin MarksChris BowdenScott A. BillerEyal C. AttarBin Wu. (2020) Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Advances 4:9, pages 1894-1905.
Crossref
Gail J. Roboz, Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, Martha L. Arellano, Will Donnellan, Harry P. Erba, Gabriel N. Mannis, Daniel A. Pollyea, Anthony S. Stein, Geoffrey L. Uy, Justin M. Watts, Amir T. Fathi, Hagop M. Kantarjian, Martin S. Tallman, Sung Choe, David Dai, Bin Fan, Hongfang Wang, Vickie Zhang, Katharine E. Yen, Stephanie M. Kapsalis, Denice Hickman, Hua Liu, Samuel V. Agresta, Bin Wu, Eyal C. Attar & Richard M. Stone. (2019) Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood.
Crossref
David Dai, Hua Yang, Salah Nabhan, Hua Liu, Denice Hickman, Guowen Liu, Jeffrey Zacher, Apinya Vutikullird, Chandra Prakash, Samuel Agresta, Chris Bowden & Bin Fan. (2019) Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects. European Journal of Clinical Pharmacology 75:8, pages 1099-1108.
Crossref
Courtney D. DiNardo & Eytan M. Stein. (2018) SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML. Clinical Lymphoma Myeloma and Leukemia 18:12, pages 769-772.
Crossref
Qiangang Zheng, Ziqi Chen, Huixin Wan, Shuai Tang, Yan Ye, Yuan Xu, Lei Jiang, Jian Ding, Meiyu Geng, Min Huang & Ying Huang. (2018) Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors. Bioorganic & Medicinal Chemistry Letters 28:23-24, pages 3808-3812.
Crossref
Courtney D. DiNardoEytan M. SteinStéphane de BottonGail J. RobozJessica K. AltmanAlice S. MimsRonan SwordsRobert H. CollinsGabriel N. MannisDaniel A. PollyeaWill DonnellanAmir T. FathiArnaud PigneuxHarry P. ErbaGabrielle T. PrinceAnthony S. SteinGeoffrey L. UyJames M. ForanElie TraerRobert K. StuartMartha L. ArellanoJames L. SlackMikkael A. SekeresChristophe WillekensSung ChoeHongfang WangVickie ZhangKatharine E. YenStephanie M. KapsalisHua YangDavid DaiBin FanMeredith GoldwasserHua LiuSam AgrestaBin WuEyal C. AttarMartin S. TallmanRichard M. StoneHagop M. Kantarjian. (2018) Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML . New England Journal of Medicine 378:25, pages 2386-2398.
Crossref
Hamoud Al-Khallaf. (2017) Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight. Cell & Bioscience 7:1.
Crossref
Qiangang Zheng, Shuai Tang, Xianlei Fu, Ziqi Chen, Yan Ye, Xiaojing Lan, Lei Jiang, Ying Huang, Jian Ding, Meiyu Geng, Min Huang & Huixin Wan. (2017) Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors. Bioorganic & Medicinal Chemistry Letters 27:23, pages 5262-5266.
Crossref
Daniel A. Arber, Michael J. Borowitz, Melissa Cessna, Joan Etzell, Kathryn Foucar, Robert P. Hasserjian, J. Douglas Rizzo, Karl Theil, Sa A. Wang, Anthony T. Smith, R. Bryan Rumble, Nicole E. Thomas & James W. Vardiman. (2017) Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology. Archives of Pathology & Laboratory Medicine 141:10, pages 1342-1393.
Crossref
Qingyu Xu, Yan Li, Na Lv, Yu Jing, Yihan Xu, Yuyan Li, Wenjun Li, Zilong Yao, Xiaosu Chen, Sai Huang, Lili Wang, Yonghui Li & Li Yu. (2017) Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Clinical Cancer Research 23:15, pages 4511-4522.
Crossref
Jae-Sook Ahn, Hyeoung-Joon Kim, Yeo-Kyeoung Kim, Seung-Shin Lee, Seo-Yeon Ahn, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Hee Jeong Park, Seung Hyun Choi, Chul Won Jung, Jun-Ho Jang, Hee Je Kim, Joon Ho Moon, Sang Kyun Sohn, Jong-Ho Won, Sung-Hyun Kim, Szardenings Michael, Mark D. Minden & Dennis Dong Hwan Kim. (2016) 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia. Oncotarget 8:5, pages 8305-8314.
Crossref
Na Wang, Fei Wang, Ningning Shan, Xiaohui Sui & Hongzhi Xu. (2017) IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes. Acta Haematologica 138:3, pages 143-151.
Crossref
Marijana Virijevic, Teodora Karan-Djurasevic, Irena Marjanovic, Natasa Tosic, Mirjana Mitrovic, Irena Djunic, Natasa Colovic, Ana Vidovic, Nada Suvajdzic-Vukovic, Dragica Tomin & Sonja Pavlovic. (2016) Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype. Radiology and Oncology 50:4, pages 385-393.
Crossref
Ol'ga Vladimirovna Blau. (2016) Genetic Mutations in Acute Myeloid Leukemia. Clinical oncohematology 9:3, pages 245-256.
Crossref
Jae-Sook Ahn, Hyeoung-Joon Kim, Yeo-Kyeoung Kim, Seun-Shin Lee, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Nan Young Kim, Seung Hyun Choi, Chul Won Jung, Jun-Ho Jang, Hee Je Kim, Joon Ho Moon, Sang Kyun Sohn, Jong-Ho Won, Sung-Hyun Kim & Dennis Dong Hwan Kim. (2016) DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 22:1, pages 61-70.
Crossref
R J Molenaar, S Thota, Y Nagata, B Patel, M Clemente, B Przychodzen, C Hirsh, A D Viny, N Hosano, F E Bleeker, M Meggendorfer, T Alpermann, Y Shiraishi, K Chiba, H Tanaka, C J F van Noorden, T Radivoyevitch, H E Carraway, H Makishima, S Miyano, M A Sekeres, S Ogawa, T Haferlach & J P Maciejewski. (2015) Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia 29:11, pages 2134-2142.
Crossref
Michael L. WangNathanael G. Bailey. (2015) Acute Myeloid Leukemia Genetics: Risk Stratification and Implications for Therapy. Archives of Pathology & Laboratory Medicine 139:10, pages 1215-1223.
Crossref
Kareem Jamani & Carolyn Owen. (2015) Update on recurrent genetic aberrations in acute myeloid leukemia. International Journal of Hematologic Oncology 4:5, pages 179-190.
Crossref
Qiu-Ling Ma, Jing-Han Wang, Yun-Gui Wang, Chao Hu, Qi-Tian Mu, Meng-Xia Yu, Lei Wang, Dong-Mei Wang, Min Yang, Xiu-Feng Yin, Fei-Fei Chen, Sha-Sha Lu, Jian Chen, Zhi-Juan Zhu, Sai-Juan Chen & Jie Jin. (2015) High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia . International Journal of Cancer 137:5, pages 1058-1065.
Crossref
Courtney D. DiNardo, Farhad Ravandi, Sam Agresta, Marina Konopleva, Koichi Takahashi, Tapan Kadia, Mark Routbort, Keyur P. Patel, Mark Brandt, Sherry Pierce, Guillermo Garcia-Manero, Jorge Cortes & Hagop Kantarjian. (2015) Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. American Journal of Hematology 90:8, pages 732-736.
Crossref
Xingyu Lu, Boxuan Simen Zhao & Chuan He. (2015) TET Family Proteins: Oxidation Activity, Interacting Molecules, and Functions in Diseases. Chemical Reviews 115:6, pages 2225-2239.
Crossref
Remco J. Molenaar, Tomas Radivoyevitch, Jaroslaw P. Maciejewski, Cornelis J.F. van Noorden & Fonnet E. Bleeker. (2014) The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1846:2, pages 326-341.
Crossref
Anne S. Roug, Marcus C. Hansen, Line Nederby & Peter Hokland. (2014) Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age. British Journal of Haematology 167:2, pages 162-176.
Crossref
Ruediger Liersch, Carsten M?ller-Tidow, Wolfgang E. Berdel & Utz Krug. (2014) Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use. British Journal of Haematology 165:1, pages 17-38.
Crossref
Yidan Zhao, Jenny Peng, Catherine Lu, Michael Hsin, Marco Mura, Licun Wu, Lei Chu, Ricardo Zamel, Tiago Machuca, Thomas Waddell, Mingyao Liu, Shaf Keshavjee, John Granton & Marc de Perrot. (2014) Metabolomic Heterogeneity of Pulmonary Arterial Hypertension. PLoS ONE 9:2, pages e88727.
Crossref
Jiang-Han Wang, Wen-Lian Chen, Jun-Min Li, Song-Fang Wu, Tian-Lu Chen, Yong-Mei Zhu, Wei-Na Zhang, Yang Li, Yun-Ping Qiu, Ai-Hua Zhao, Jian-Qing Mi, Jie JinYun-Gui WangQiu-Ling MaHe HuangDe-Pei WuQin-Rong WangYan LiXiao-Jing YanJin-Song YanJian-Yong Li, Shuai Wang, Xiao-Jun Huang, Bing-Shun WangWei Jia, Yang Shen, Zhu Chen & Sai-Juan Chen. (2013) Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proceedings of the National Academy of Sciences 110:42, pages 17017-17022.
Crossref
Velizar Shivarov, Milena Ivanova, Evgueniy Hadjiev & Elissaveta Naumova. (2013) Novel Multiplex Bead-Based Assay for Detection of IDH1 and IDH2 Mutations in Myeloid Malignancies. PLoS ONE 8:9, pages e76944.
Crossref
Courtney D. DiNardoKathleen J. PropertAlison W. LorenElisabeth PaiettaZhuoxin SunRoss L. LevineKimberly S. StraleyKatharine YenJay P. PatelSamuel AgrestaOmar Abdel-WahabAlexander E. PerlMark R. LitzowJacob M. RoweHillard M. Lazarus, Hugo F. Fernandez, David J. MargolisMartin S. TallmanSelina M. LugerMartin Carroll. (2013) Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 121:24, pages 4917-4924.
Crossref
Julie-Aurore Losman & William G. KaelinJr.Jr.. (2013) What a difference a hydroxyl makes: mutant IDH, ( R )-2-hydroxyglutarate, and cancer . Genes & Development 27:8, pages 836-852.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.